Alzprotect

Alzprotect is a French biopharmaceutical company founded in 2007 and based in Lille, focused on developing innovative small molecule therapeutics for neurodegenerative diseases. The company's mission is to design treatments that can halt neurodegeneration and restore brain functions, with a primary focus on tauopathies such as Progressive Supranuclear Palsy (PSP) and Alzheimer's disease. Its lead asset, AZP2006, is distinguished by a novel multi-target mechanism of action.